Company Panacea Life Sciences Holdings, Inc.

PLSH

US69810P1093

Pharmaceuticals

Delayed OTC Markets Other stock markets 02:32:32 2025-06-13 pm EDT			5-day change	1st Jan Change
0.0366 ^USD	-2.27%		-2.40%	+46.40%

2024	Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2024	Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Business description: Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc. is a holding company organized as a plant-based natural health ingredient and product company. It specializes in the development, manufacturing, research, and distribution of products with natural health and wellness market segment for both humans and animals. The Companyâs subsidiary, Panacea Life Sciences, Inc. (PLS) is engaged in the production, distribution, research, and manufacturing of nutraceuticals, cannabinoids, mushrooms, kratom, and other natural, plant-based ingredients and products. The Company also offers natural remedies within its branded product lines for every aspect of life, including PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure, and PANA Life. It also operates 51,000 square foot current good manufacturing practice (cGMP) facility located in Golden, Colorado. The Company, through Panacea Life Sciences Holdings, Inc., manages six retail locations and a distribution center situated in the Tampa, Florida area.

Number of employees: 40

Sales by Activity: Panacea Life Sciences Holdings, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Pharmaceuticals	2.2M	9.02M	2.06M	1.63M	2.38M

See all business segments

Geographical breakdown of sales: Panacea Life Sciences Holdings, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
United States	2.2M	9.02M	2.06M	1.63M	2.38M

See all geographic segments

Executive Committee: Panacea Life Sciences Holdings, Inc.

Manager	Title	Age	Since
Leslie Buttorff CEO	Chief Executive Officer	68	2021-06-29
Nick Cavarra PSD	President	-	-
James Baumgartner CTO	Chief Tech/Sci/R&D Officer	60	2016-12-31
Nathan Berman AUD	Comptroller/Controller/Auditor	37	-

See PANACEA LIFE SCIENCES HOLDINGS, INC. governance

Composition of the Board of Directors: Panacea Life Sciences Holdings, Inc.

Director	Title	Age	Since
Leslie Buttorff CHM	Chairman	68	2021-06-29
Lawrence Wert BRD	Director/Board Member	67	2020-04-28

Composition of the Board of Directors

Shareholders: Panacea Life Sciences Holdings, Inc.

Name	Equities	%	Valuation
Leslie Buttorff 42.73 %	8,657,526	42.73 %	320 328 $
Nick Cavarra 3.933 %	796,957	3.933 %	29 487 $
Lawrence Wert 3 %	607,868	3 %	22 491 $
Nathan Berman 0.3344 %	67,749	0.3344 %	2 507 $

Name	Equities	%	Valuation
Ceed2med LLC 100 %	10,000	100 %	800 $

Name	Equities	%	Valuation
Velocity Health Capital, Inc. 2.186 %	168,000	2.186 %	6 216 $

Name	Equities	%	Valuation
Leslie Buttorff 100 %	10,000	100 %	370 $

Name	Equities	%	Valuation
Leslie Buttorff 100 %	100	100 %	4 $

Name	Equities	%	Valuation
Leslie Buttorff 0.4545 %	10,000	0.4545 %	370 $

List of PANACEA LIFE SCIENCES HOLDINGS, INC. shareholders

Company details: Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc.

5910 South University Boulevard Suite C18-193

80121, Greenwood Village

http://www.panacealife.com

address Panacea Life Sciences Holdings, Inc.(PLSH)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PANACEA LIFE SCIENCES HOLDINGS, INC.	-2.27%	-2.40%	-58.92%	-90.14%	777K
ELI LILLY AND COMPANY	-1.24%	-2.95%	-11.97%	+163.93%	710B
JOHNSON & JOHNSON	-0.76%	-2.49%	+3.95%	-12.49%	367B
NOVO NORDISK A/S	-1.13%	-6.62%	-50.83%	+26.76%	335B
ABBVIE INC.	+0.34%	-2.58%	+8.86%	+30.03%	328B
ROCHE HOLDING AG	-0.96%	-4.00%	+4.52%	-14.91%	258B
NOVARTIS AG	-0.63%	-2.09%	+1.95%	+19.25%	230B
ASTRAZENECA PLC	-1.07%	-3.28%	-15.05%	+4.91%	223B
MERCK & CO., INC.	+1.18%	-1.22%	-38.01%	-9.87%	197B
AMGEN INC.	-0.13%	-0.54%	-5.15%	+21.73%	156B
Average	-0.69%	-1.67%	-16.06%	+13.92%	280.25B
Weighted average by Cap.	-0.68%	-0.45%	-11.12%	+47.74%